Schizophrenia Research
Volume 106, Issue 2 , Pages 286-293 , December 2008

Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis

  • Cheryl M. Corcoran

      Affiliations

    • Columbia University, Department of Psychiatry, New York, NY, United States
    • Corresponding Author InformationCorresponding author. New York State Psychiatric Institute, 1051 Riverside Drive, New York, New York 10032, United States.
    • ,
  • David Kimhy

      Affiliations

    • Columbia University, Department of Psychiatry, New York, NY, United States
    • ,
  • Arielle Stanford

      Affiliations

    • Columbia University, Department of Psychiatry, New York, NY, United States
    • ,
  • Shamir Khan

      Affiliations

    • Columbia University, Department of Psychiatry, New York, NY, United States
    • ,
  • Julie Walsh

      Affiliations

    • Columbia University, Department of Psychiatry, New York, NY, United States
    • ,
  • Judy Thompson

      Affiliations

    • Columbia University, Department of Psychiatry, New York, NY, United States
    • ,
  • Scott Schobel

      Affiliations

    • Columbia University, Department of Psychiatry, New York, NY, United States
    • ,
  • Jill Harkavy-Friedman

      Affiliations

    • Columbia University, Department of Psychiatry, New York, NY, United States
    • ,
  • Ray Goetz

      Affiliations

    • Columbia University, Department of Psychiatry, New York, NY, United States
    • ,
  • Tiziano Colibazzi

      Affiliations

    • Columbia University, Department of Psychiatry, New York, NY, United States
    • ,
  • Victoria Cressman

      Affiliations

    • Columbia University, Department of Psychiatry, New York, NY, United States
    • ,
  • Dolores Malaspina

      Affiliations

    • Columbia University, Department of Psychiatry, New York, NY, United States
    • New York University, Department of Psychiatry, New York, NY, United States

Received 24 January 2008 ,Revised 6 August 2008 ,Accepted 11 August 2008.

References 

  1. Arsenault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. B.M.J. 2002;325:1212–1213
  2. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry. 2004;184:110–117
  3. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry. 2008;65(1):28–37
  4. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol. Psychiatry. 2005;57(10):1117–1127
  5. Cuffel BJ, Heithoff KA, Lawson W. Correlates of patterns of substance abuse among patients with schizophrenia. Hosp. Community Psychiatry. 1993;44(3):247–251
  6. Diggle PJ, Liang KY, Zeger SL. Analysis of Longitudinal Data. Oxford: Clarendon Press; 1994;
  7. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29(8):1558–1572
  8. Hambrecht M, Häfner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust. N. Z. J. Psychiatry. 2000;34(3):468–475
  9. Hamilton M. Hamilton Anxiety Scale. In:  Guy W editors. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: NIMH; 1976;
  10. Haroun N, Dunn L, Haroun A, Cadenhead KS. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr. Bull. 2006;32(1):166–178
  11. Haroun N, Dunn L, Haroun A, Cadenhead KS. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr. Bull. 2006;32:166–178
  12. Hawkins KA, McGlashan TH, Quinlan D, Miller TJ, Perkins DO, Zipursky RB, et al. Factorial structure of the scale of prodromal symptoms. Schizophr. Res. 2004;68(2–3):339–347
  13. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M, et al. An experimental study of catechol-O-methyltransferase Val(158)Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology. 2006;31(12):2748–2757
  14. Hides L, Dawe S, Kavanagh DJ, Young RM. Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br. J. Psychiatry. 2006;189:137–143
  15. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS—PL): initial reliability and validity data. J. Am. Acad. Child Adolesc. Psychiatry. 1997;36:980–988
  16. Kendler KS, Gallagher TJ, Abelson JM, Kessler RC. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch. Gen. Psychiatry. 1996;53(11):1022–1031
  17. Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res. 2007;151(1–2):151–154
  18. Koethe D, Gerth CW, Neatby MA, Haensel A, Thies M, Schneider U, et al. Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness. Schizophr. Res. 2006;88(1–3):142–150
  19. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt B. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr. Res. 2004;68(1):37–48
  20. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt B. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr. Res. 2004;68:37–48
  21. Meyer SE, Bearden CE, Lux SR, Gordon JL, Johnson JK, O'Brien MP, et al. The psychosis prodrome in adolescent patients viewed through the lens of DSM-IV. J. Child Adolesc. Psychopharmacol. 2005;15(3):434–451
  22. Miller P, Lawrie SM, Hodges A, Clafferty R, Cosway R, Johnstone EC. Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia. Soc. Psychiatry Psychiatr. Epidemiol. 2001;36(7):338–342
  23. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr. Bull. 2003;29(4):703–715
  24. Miller PM, Johnstone EC, Lawrie SM, Owens DGC. Substance use, psychiatric symptoms and the onset of schizophrenic illness. J. Subst. Abuse. 2006;11(2):101–113
  25. Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319–328
  26. Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: the hash realities. Nat. Rev. Neurosci. 2007;8(11):885–895
  27. Nurnberger JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch. Gen. Psychiatry. 1994;51(11):849–859
  28. Pencer A, Addington J. Substance use and cognition in early psychosis. J. Psychiatry Neurosci. 2003;28(1):48–54
  29. Phillips LJ, Curry C, Yung AR, Yuen HP, Adlard S, McGorry PD. Cannabis use is not associated with the development of psychosis in an ‘ultra’ high-risk group. Aust. N. Z. J. Psychiatry. 2002;36(6):800–806
  30. Preda A, Miller TJ, Rosen JL, Somjee L, McGlashan TH, Woods SW. Treatment histories of patients with a syndrome putatively prodromal to schizophrenia. Psychiatr. Serv. 2002;53(3):342–344
  31. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. J.A.M.A. 1990;264(19):2511–2518
  32. Rosen JL, Miller TJ, D'Andrea JT, McGlashan TH, Woods SW. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr. Res. 2006;85:124–131
  33. Sevy S, Robinson DG, Holloway S, Alvir JM, Woerner MG, Bilder R, et al. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr. Scand. 2001;104(5):367–374
  34. Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr. Res. 2005;75:135–137
  35. Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend. 1996;42(3):201–207
  36. Van Mastrigt S, Addington J, Addington D. Substance misuse at presentation to an early psychosis program. Soc. Psychiatry Epidemiol. 2003;156(4):319–327
  37. Verdoux H, Gindre C, Sorbara F, Tournier M, Swendsen JD. Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychol. Med. 2003;33(1):23–32
  38. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res. 2001;107(3):173–177
  39. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr. Res. 2004;67(2–3):131–142

PII: S0920-9964(08)00371-X

doi: 10.1016/j.schres.2008.08.008

Schizophrenia Research
Volume 106, Issue 2 , Pages 286-293 , December 2008

Article Tools